ALVIMOPAN

Alvimopan Overview

Alvimopan is an oral prescription medication utilized primarily within Gastroenterology, General Surgery, and Post-Anesthesia Care Units. As a single active ingredient formulation of a peripheral mu-opioid receptor antagonist, it is designed specifically to counteract the gastrointestinal side effects of opioid medications without reversing pain relief.

It is indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis. By preventing opioid-induced bowel dysfunction, it helps patients recover bowel function faster, reducing post-operative complications and shortening hospital stays. It is restricted strictly to short-term inpatient hospital use.

What Is It and How Does It Work?

Alvimopan operates through a highly selective mechanism designed to act only in the digestive tract while sparing the central nervous system.

It works through targeted receptor blockade:

• Selective Peripheral Antagonism: Opioids prescribed for surgical pain bind to mu-opioid receptors in the brain to relieve pain, but they also bind to mu-opioid receptors in the gastrointestinal tract, causing muscle paralysis in the gut (postoperative ileus). Alvimopan selectively binds to these gut receptors and blocks opioids from binding to them.
• Restoring Motility: By blocking opioid binding in the intestines, alvimopan prevents opioid-induced slowing of gastrointestinal motility, allowing food and gas to move normally through the digestive tract.
• Blood-Brain Barrier Exclusion: Due to its chemical structure, alvimopan has extremely low systemic absorption and cannot easily cross the blood-brain barrier. Therefore, it does not counteract the pain-relieving effects of opioids in the brain or trigger opioid withdrawal.

Is It FDA Approved?

Yes. Alvimopan is a fully evaluated and FDA-approved oral medication.

What Is It Used For?

Federal health regulators have authorized this medication for the following specific indication:

• Postoperative Ileus Prevention: Indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis.

Before Taking This Medication: Contraindications & Precautions

Who Should Not Take This Medication?

• Patients who have taken therapeutic doses of opioids for more than 7 consecutive days immediately prior to starting alvimopan (due to a high risk of severe gastrointestinal hypersensitivity/cramping).
• Patients with severe hepatic (liver) impairment.
• Patients with end-stage renal disease (ESRD).
• Patients with a known hypersensitivity or allergy to alvimopan or any of its formulation ingredients.

Pregnancy & Breastfeeding

Alvimopan is classified as a Pregnancy Category B drug based on animal studies showing no evidence of harm to the fetus. However, there are no adequate and well-controlled studies in pregnant women; it should be used during pregnancy only if clearly needed. It is unknown if alvimopan is excreted in human breast milk, but because systemic absorption is low, levels in milk are expected to be minimal.

Tell Your Doctor Before Taking It

Inform your surgical and clinical care team if you have a history of heart disease, prior heart attacks, liver problems, or severe kidney disease. It is critical to disclose all recent opioid use (such as daily pain pills taken at home before surgery), as pre-existing heavy opioid use changes how your body reacts to the drug.

Dosage & Administration

Alvimopan is administered strictly in an inpatient hospital setting by healthcare professionals according to a rigid dosing schedule.

Standard Dosing

The medication is supplied as a 12 mg oral capsule.

• Initial Pre-Operative Dose: 12 mg administered orally prior to surgery (can be administered between 30 minutes to 5 hours prior to the surgical incision).
• Post-Operative Maintenance Dosing: 12 mg administered orally twice daily starting the day after surgery.
• Duration Limit: Administered for a maximum duration of 7 days, or until discharge, not to exceed a total of 15 doses.

How It Is Administered

• Swallowed whole with water.
• Can be taken with or without food.
• Because it is restricted to hospital use, patients will not receive a bottle of pills to take home after discharge.

Clinical Efficacy

Alvimopan has demonstrated significant clinical benefit in major abdominal surgical procedures. Clinical trials show that patients treated with alvimopan achieve faster time to first flatus (passing gas) and bowel movement, and tolerate solid food sooner compared to placebo. By shortening the duration of postoperative ileus, alvimopan significantly reduces hospital length of stay by roughly 15 to 20 hours on average, helping surgical patients recover faster and safer.

Side Effects & Safety Profile

Because alvimopan acts primarily in the gut and is given to patients recovering from major bowel surgery, its side effects are mostly gastrointestinal.

Common Side Effects

• Dyspepsia (heartburn or stomach upset).
• Hypokalemia (low levels of potassium in the blood).
• Abdominal pain or flatulence.
• Constipation or nausea.

Serious Adverse Events

• Myocardial Infarction: An elevated risk of heart attack seen with extended, off-label chronic use (hence the strict 15-dose limit).
• Severe Gastrointestinal Pain: In patients who have been taking daily opioids for more than 7 days prior to surgery, alvimopan can trigger severe abdominal cramping, diarrhea, and nausea due to sudden local opioid withdrawal in the gut.

Managing Side Effects

Postoperative stomach discomfort and electrolyte changes are routinely monitored and managed by the hospital nursing and surgical teams through standard IV fluids and supportive medications.

Drug Interactions & What to Avoid

Key Interactions

• Opioid Analgesics: While alvimopan is designed to be given alongside opioids, patients who have been on chronic daily opioids (more than 7 days) prior to surgery may experience intense gut cramping if given alvimopan.
• P-glycoprotein (P-gp) Inhibitors: Co-administration with strong P-gp inhibitors (like cyclosporine) can increase plasma concentrations of alvimopan, though clinical dose adjustments are generally not required due to the short duration of treatment.

Food & Alcohol

Food interactions are negligible; the drug can be taken without regard to meals. Alcohol consumption is not applicable, as this drug is administered solely to hospitalized surgical inpatients.

Missed Dose, Overdose & Storage

Missed Dose

Because this medication is administered by hospital staff according to a surgical care plan, missed doses are handled directly by nursing staff. If a dose is missed, it should be given as soon as possible, provided the total duration does not exceed 15 doses.

Overdose

Overdose data is limited. Single doses up to 120 mg and multiple doses up to 24 mg twice daily have been evaluated without serious acute toxicity. Treatment of accidental overdose consists of general supportive care.

Storage Instructions

Stored at controlled room temperature between 20°C and 25°C (68°F to 77°F) in hospital pharmacies and surgical supply units. Kept in its original packaging until dispensed to the inpatient.

Patient Management & Guidelines

Tests Before & During Treatment

• Serum Potassium and Electrolytes: Monitored routinely in surgical wards to watch for hypokalemia.
• Assessment of Bowel Function: Nursing staff will check for the return of bowel sounds, passing of gas, and tolerance of liquid/solid diets.
• Opioid Usage History Check: Clinical screening to ensure the patient has not been on continuous daily opioids for more than 7 days prior to admission.

Do’s and Don’ts

• DO inform your surgical team about all pain medications you took at home leading up to your surgery.
• DO swallow the capsules whole when your hospital nurse hands them to you.
• DON’T expect or attempt to get a prescription for alvimopan to take at home after discharge.
• DON’T take alvimopan if you have severe, chronic liver failure.

Frequently Asked Questions

References

• U.S. Food and Drug Administration (FDA) – Alvimopan prescribing information.
• Drugs@FDA Overview – Alvimopan.
• American Society of Colon and Rectal Surgeons (ASCRS) – Guidelines for Perioperative Care in Intestinal Surgery.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider regarding medical conditions or treatment plans.